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Abstract
Background: The c-Myb transcription factor is essential for the maintenance of stem-progenitor cells in bone
marrow, colon epithelia, and neurogenic niches. c-Myb malfunction contributes to several types of malignancies
including breast cancer. However, the function of c-Myb in the metastatic spread of breast tumors remains
unexplored. In this study, we report a novel role of c-Myb in the control of specific proteases that regulate the
matrix-dependent invasion of breast cancer cells.
Results: Ectopically expressed c-Myb enhanced migration and ability of human MDA-MB-231 and mouse 4T1
mammary cancer cells to invade Matrigel but not the collagen I matrix in vitro. c-Myb strongly increased the
expression/activity of cathepsin D and matrix metalloproteinase (MMP) 9 and significantly downregulated MMP1.
The gene coding for cathepsin D was suggested as the c-Myb-responsive gene and downstream effector of the
migration-promoting function of c-Myb. Finally, we demonstrated that c-Myb delayed the growth of mammary
tumors in BALB/c mice and affected the metastatic potential of breast cancer cells in an organ-specific manner.
Conclusions: This study identified c-Myb as a matrix-dependent regulator of invasive behavior of breast cancer
cells.
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Background
Metastatic disease is the main cause of death in cancer
patients. The interaction of tumor cells with local
stroma plays a critical role in metastatic dissemination
and determines metastasis organotropism. Identification
of the genes providing cancer cells with the abilities to
disseminate to specific organs is essential for targeting
metastatic cells to improve patient survival.
The c-Myb protein is a transcription factor that plays
a key role in regulating the proliferation/differentiation
of progenitor cells in bone marrow, colonic crypts, and
neurogenic niches [1]. c-myb was originally identified as
a cellular homolog of v-myb, the transforming retroviral
oncogene linked to avian leukemia [2]. Since then, c-
myb has been characterized as an oncogene in several
human tumor types [3-7], including breast cancer
[8-10]. The role of c-Myb in stimulating cell prolifera-
tion, suppressing differentiation, and apoptosis is well
established [1,11]. However, only a few reports concern-
ing the role of c-Myb in controlling tumor invasion
have been reported. First, genes coding for some of the
proinvasive factors, such as CXCL12 and CXCR4, were
identified as c-Myb targets [12-14]. Second, c-Myb is
involved in the regulation of epithelial-to-mesenchymal
transition (EMT) and invasion in neuroblastoma, colon
carcinoma, and embryonic kidney cells through the
upregulation of the transcription repressor Slug [15].
Third, in hepatocellular carcinoma cells, c-Myb
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tin [16]. Interestingly, the depletion of endogenous
c-myb in MCF7 breast cancer cells increased tumorigen-
esis in vitro and in vivo, suggesting that c-Myb acts as a
tumor suppressor in breast cancer [17]. However, how
c-Myb controls breast carcinoma progression and disse-
mination remains unresolved. To gain insight into this
process, we generated variants of mammary carcinoma
cell lines overexpressing c-myb and investigated their
migratory/invasive and metastatic capabilities. We
demonstrated that c-Myb regulates the invasive behavior
of breast cancer cells in a matrix-dependent manner,
possibly via a novel signaling axis causing the deregula-
tion of MMP1, MMP9, and cathepsin D expression.
Results
Ectopically expressed c-myb increases the migration and
invasion of MDA-MB-231 cells through Matrigel in vitro
First, variants of MDA-MB-231 cells overexpressing
c-myb were derived as described in the Material and
Methods. The expression of c-myb in individual clones
of MDA-MB-231MYBup cells significantly exceeded
that in non-transfected and myb-less vector-transfected
controls, as determined by qRT-PCR and immunoblot-
ting (Figure 1A, B). The exogenous c-Myb protein pro-
duced in MDA-MB-231MYBup cells was capable of
transactivating the model reporter gene from a promo-
ter containing the Myb-binding sites (Figure 1C).
Next, we assessed the migration and invasion of
MDA-MB-231MYBup cells using the Cultrex cell inva-
sion assay (Trevigen, Gaithersberg, MD). We found that
exogenous c-Myb enhanced the migration and invasion
of MDA-MB-231 cells through Matrigel (Figure 2).
To verify these data and to evaluate the kinetics of
migration/invasion of the MDA-MB-231MYBup cells in
real time, we used the xCELLigence RTCA. The number
of migrating or invasive cells can be monitored continu-
ously and expressed as the cell index in this assay [18].
The cell index profiles revealed the rapid onset of
c-Myb-induced MDA-MB-231MYBup cell migration
(Figure 3A). For statistical analysis, we used the cell
index values obtained 6 h after the starting point. The
MDA-MB-231MYBup clones were significantly (p <
0.05) more active (1.5- and 1.7-fold) in migration than
control cells at this time point (Figure 3B). Similar
results were obtained also for 4- and 8-h time points
(Additional file 1). Next, the kinetics of cell invasion
was analyzed using Matrigel as a surrogate basement
membrane (BM) by the same approach. We found that
c-Myb substantially accelerated the invasion of MDA-
MB-231 cells (Figure 3C). For statistical analysis of inva-
sion rate, the cell index values determined at the 12-h
time points were used. Our results demonstrated
that c-myb overexpression significantly increased
(2.4- and 2.5-fold, p < 0.05) the ability of MDA-MB-231
cells to invade Matrigel in vitro (Figure 3D). Similar
results were obtained also for 10- and 16-h time points
(Additional file 1).
Figure 1 Derivation of MDA-MB-231 cells overexpressing
c-myb. The MDA-MB-231 cells were transfected with human c-myb
cDNA (MYBup) or the myb-less vector (vector) by lipofection. Pools of
G418-resistant cells were cloned. (A)c - myb expression was determined
in two independent clones by qRT-PCR. GAPDH was used as an
internal control. (B) The c-Myb protein in two independent MYBup
clones was determined by immunoblotting, and b-actin was used as a
loading control. (C) Transactivation by c-Myb was determined by a
luciferase assay using p6MBSluc as a reporter. The luciferase activity of
each sample was expressed in relative light units and normalized for
transfection efficiency according to the b-galactosidase activity. The
columns show the average relative luciferase activity from three
independent experiments. Error bars indicate standard deviations.
Marks * and ** indicate significant (p < 0.05 and p < 0.01, respectively)
differences in the relative amounts of c-myb mRNA (A) and in the
luciferase activity (C)i nt h emyb-less vector-transfected cells and
MYBup cells as determined by the t-test.
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responsible for increased migration and Matrigel inva-
siveness of MDA-MB-231MYBup cells, we specifically
silenced c-myb expression in these cells using siRNA
and monitored cell migration/invasion again. We found
that cell migration and Matrigel penetration were signif-
icantly restrained in the MDA-MB-231MYBup cells
transfected with the c-myb-specific siRNA (Additional
file 2). This confirms that c-Myb upregulates migration
and invasiveness of these cells indeed.
c-Myb does not stimulate cell invasion through the
collagen I matrix
To evaluate the invasive capacity of cancer cells within
the stromal matrix, the collagen I gel is a suitable matrix
barrier [19,20]. Therefore, membranes of the CIM-plates
16 were coated with collagen I matrix, and cell invasion
was measured in real time using the xCELLigence RTCA.
The cell indexes were determined at the 12-h time points
to compare the invasion rates of c-myb-overexpressing
and control cells. We found that c-Myb did not enhance
the ability of MDA-MB-231MYBup cells to penetrate the
collagen I matrix barrier (Figure 3E, F). Similar results
were obtained also for 10- and 16-h time points (data
not shown). This suggests that c-Myb-induced tumor
cell invasion in vitro depends on composition of the
substrate/matrix.
c-Myb upregulates cathepsin D and MMP9 and
downregulates MMP1
Tumor cells acquire ability to surmount extracellular
matrix (ECM) barriers by expressing a range of pro-
t e a s e s ,s u c ha sM M P so rc a t h e p s i n s[ 2 1 ] .V a r i o u s
enzymes are vital for the degradation of either BMs or
stromal matrices [22-24]. We found that Matrigel inva-
sion by MDA-MB-231MYBup cells is sensitive to the
broad spectrum MMP inhibitor GM6001 (Ilomastat;
Additional file 3) suggesting that some of MMPs are
responsible for this effect. To further specify the
c-Myb-targeted proteases, we first determined the rela-
tive amounts of MMP1, 2, 3, 7, 9, 10, 11, 13,a n d
cathepsin D mRNAs in MDA-MB-231MYBup cells
by qRT-PCR. Out of eight MMPs tested, only MMP9
(92-kDa gelatinase) was significantly upregulated
( 2 - f o l d ,p<0 . 0 1 )i nM Y B u pc e l l s( F i g u r e4 A ) .S i m i -
larly, the cathepsin D mRNA was upregulated more
than 2-fold (p < 0.05) in the same cells (Figure 4A).
Interestingly, the level of MMP1 (interstitial collage-
nase) mRNA dropped by 60% in the MYBup clones
(p < 0.05; Figure 4A). The c-Myb-dependent changes
of relative amounts of MMP1 and MMP9 mRNAs
were reflected also in amounts of MMP1 and MMP9
proteins produced by these cells as determined by
immunoblotting (Figure 4B). Whereas c-Myb decreased
the expression/secretion of MMP1 in MDA-MB-
231MYBup cells, it increased the expression/secretion
of MMP9 (Figure 4B). Cathepsin D is another enzyme
involved in cell invasion and metastasis, particularly in
breast cancer [25]. Several components of ECM, such as
fibronectin, proteoglycans, and collagens, are substrates
for this lysosomal aspartic protease [25-27]. The level of
cathepsin D in MDA-MB-231MYBup cell lysates and
conditioned media was determined by immunoblotting.
We found that the production of both intracellular and
extracellular cathepsin D by MDA-MB-231MYBup cells
was higher than that by control cells (Figure 4B). In
addition, the enzymatic activity of cathepsin D was also
significantly upregulated in the MYBup cells of
both clones as determined by the Cathepsin D Assay
(Figure 4C). These results document that c-Myb can
substantially affect the spectrum and activities of
proteases produced by MDA-MB-231 cells.
Figure 2 Overexpression of c-Myb increases the migration and invasiveness of MDA-MB-231 cells through the basement membrane
extract/Matrigel.( A) The transmigration assay was performed using Cultrex Cell Invasion Assay. MDA-MB-231MYBup and control cells migrating
through a microporous membrane towards the chemoattractant (10% FCS)-containing medium were stained with the Calcein-AM. Cell migration
was quantified according to the emitted fluorescence using the Synergy HT microplate reader. The columns show the average values of
fluorescence from three independent measurements. (B) To determine cell invasiveness, the membrane was covered with a layer of the
basement membrane matrix and the experiment was performed as described above. Error bars indicate the standard deviations. Asterisks
indicate significant (p < 0.05) differences in the migration (A) and invasion (B) of the myb-less vector-transfected and MYBup cells as determined
by the t-test.
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a transcriptional mechanism
To elucidate the mechanism by which c-Myb regulates
MMP9, MMP1, and cathepsin D in MYBup cells, we
first examined whether c-Myb can activate transcription
of cathepsin D. We performed transactivation assays
using two variants of the luciferase reporter: one con-
taining 2.85-kb promoter of cathepsin D and the other
equipped with the 0.82-kb promoter of cathepsin D.
The MDA-MB-231MYBup and control cells were transi-
ently transfected with either of the reporter plasmids
and harvested 24 h later. Luciferase assays using both
reporters revealed significant upregulation of the lucifer-
ase expression from the cathepsin D promoter in MDA-
MB-231MYBup cells (Figure 4D). In contrast, c-Myb
failed to transactivate the luciferase reporter from the
MMP9 (1.38 kb) and MMP1 (4.3, 1.606, and 0.624 kb)
promoter sequences (Figure 4D). This suggests that
Figure 3 Kinetics of c-Myb-induced migration and Matrigel invasion of MDA-MB-231MYBup cells. Cell migration/invasion in real time was
analyzed by the xCELLigence RTCA. The control MDA-MB-231 (wt, vector), and the c-myb-transfected (M2, M5) cells were seeded at a density of
7.5 × 10
4 per well and cultured in the chambers of CIM-plates. For the cell migration experiments, the membranes were left uncoated (A, B). For
monitoring cell invasion, the membranes were coated with either Matrigel (C, D) or collagen I (E, F) as described in the Material and Methods.
The bottom chambers were filled with either complete medium containing 10% FCS as a chemoattractant or with serum-free medium (-) in
control wells. The charts show the representative outcomes of kinetics analysis of cell migration (A), Matrigel invasion (C) and collagen I invasion
(E). The panels (B, D, F) show the average cell indexes at certain time points (6 h for migration and 12 h for invasion) from seven (migration)
and five (invasion) independent measurements. Error bars indicate standard deviations. Asterisks indicate significant (p < 0.05) differences in the
migration (B) and Matrigel invasion (D) of the myb-less vector-transfected cells and MYBup cells as determined by the t-test.
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not MMP9 and MMP1 promoters in transiently trans-
fected plasmid reporters.
Upregulation of cathepsin D by c-Myb contributes to cell
migration and invasion
To confirm the role of cathepsin D in c-Myb-induced
cell migration/invasion, we performed RNAi-mediated
silencing of cathepsin D in MDA-MB-231MYBup cells,
resulting in effective reduction of the endogenous cathe-
psin D protein (Figure 5A). The MDA-MB-231MYBup
cells with reduced cathepsin D production were sub-
stantially less active in migration and invasion through
Matrigel and collagen I than MDA-MB-231MYBup cells
transfected with control siRNA as determined using the
xCELLigence RTCA system (Figure 5B, C). These results
Figure 4 c-Myb upregulates cathepsin D and MMP9 and downregulates MMP1 in MDA-MB-231MYBup cells.( A) The relative amounts of
MMP2, 3, 7, 10, 11, and 13 mRNA in the MYBup 5 and myb-less vector-transfected cells were determined by qRT-PCR. The relative amounts of
MMP1, 9 and cathepsin D mRNAs were also determined in the MYBup 2 clone. Marks * and ** indicate significant (p < 0.05 and p < 0.01,
respectively) differences in the relative amounts of cathepsin D, MMP9, and MMP1 mRNA in the myb-less vector-transfected and MYBup cells as
determined by the t-test. The columns show the average values of relative normalized expression of the indicated genes from at least three
independent experiments. (B) The control (wt, vector) and the MYBup cell protein extracts were analyzed by immunoblotting with anti-MMP1,
anti-MMP9, and anti-cathepsin D antibodies. The secretion of cathepsin D, MMP9, and MMP1 was determined in the cell-conditioned medium.
Equal amounts of total proteins were loaded. (C) To determine the activity of cathepsin D, protein extracts were prepared from harvested cells
as described in the Material and Methods. The extent of hydrolysis of the fluorimetric substrate was measured in real time using a Synergy HT
microplate reader. To demonstrate the assay specificity, pepstatin A was added to inhibit cathepsin D activity (data shown for MYBup 5 cells). (D)
Transactivation assays were performed using six variants of luciferase reporters: two for cathepsin D (either containing the 2.85-kb or 0.82-kb
promoter sequence), one for MMP9 (1.38 kb), and three for MMP1 (0.624, 1.606, and 4.3 kb). The luciferase activity of each sample was expressed
in relative light units and normalized for transfection efficiency according to the b-galactosidase activity. The columns show the average values
of relative luciferase activity from three independent measurements. Marks * and ** indicate significant (p < 0.05 and p < 0.01, respectively)
differences in the luciferase activities in control cells and MYBup cells as determined by the t-test.
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induced migration and invasion of MDA-MB-231 cells.
c-Myb delays mammary tumor growth and prevents
pulmonary metastasis
To verify that the effects of c-Myb described in MDA-
MB-231 cells are not limited to this particular cell line,
we generated variants of murine 4T1 breast cancer cells
overexpressing murine c-myb. The 4T1MYBup cells
were tested for c-myb expression, cell migration, and
Matrigel/collagen I invasion. Exogenous murine c-Myb
was clearly present in 4T1MYBup cells (Figure 6A) and
was proficient to activate transcription of the reporter
gene from its responsive elements (data not shown) as
well as stimulate cell migration and Matrigel invasion
(Figure 6B, C). As observed in the MDA-MB-
231MYBup cells, the c-Myb-induced invasion of 4T1
cells was limited to Matrigel matrices, and it did not
occur in the collagen I matrices (Figure 6C).
Next, we wished to investigate behavior of the c-myb-
overexpressing cancer cells in vivo.W eu s e dt h e
4T1MYBup cells in a syngeneic mouse mammary tumor
model. The tumor growth and spontaneous metastatic
ability of the myb-less vector-transfected 4T1 and
4T1MYBup cell variants were compared following
orthotopic inoculation into BALB/c mice. The c-myb-
overexpressing tumors grew at a significantly slower
rate than control 4T1 tumors. After 27 days, the aver-
age tumor size was larger in control mice injected
with cells containing the myb-less vector (954 ± 310
mm
3) than in mice injected with cells expressing
c-myb (360 ± 212 mm
3; p < 0.05; Figure 7A). When
the mean tumor diameter reached 1.2 cm, the mice
were sacrificed, and the tumors were excised. The
average tumor weight at harvest was approximately
the same in both groups (data not shown). Although
all mice in control group developed lung metastases
(n = 9), pulmonary metastases were observed only in
22% of mice in the group injected with cells overex-
pressing c-myb (Figure 7B). In addition, the average
number of metastatic nodules in lung was significantly
(p < 0.01) higher in the control group than in the
group injected with the MYBup variants (Figure 7C).
Both groups consistently developed liver and bone
Figure 5 siRNA-mediated cathepsin D silencing reduces the migration and invasion of MDA-MB-231MYBup cells. MDA-MB-231MYBup
cells were transfected with cathepsin D (CD) or control (ctrl) siRNA as described in the Material and Methods. (A) The level of cathepsin D
protein in these cells was determined by immunoblotting. A representative western blot is presented. (B) Migration and invasion activities of the
same cells were determined by the xCELLigence RTCA. The chart shows the representative outcomes of the kinetics analysis of cell migration.
(C) The average cell indexes at the 6-h (migration, left) and 12-h (invasion, right) time points, respectively, from five independent measurements
are shown. Error bars indicate standard deviations. Marks * and ** indicate significant (p < 0.05 and p < 0.01, respectively) differences in the
migration/invasion of the cells transfected with cathepsin D siRNA and control siRNA as determined by the t-test.
Figure 6 c-Myb affects cell migration/invasion in murine 4T1 cells similarly as observed in MDA-MB-231 cells. 4T1 cells were transfected
with murine c-myb cDNA (M-M5, M-M8) or with the myb-less vector (vector) by lipofection. G418-resistant cells were selected and cloned. (A)c -
myb expression in both cell variants (vector and MYBup, respectively) and nontransfected cells (wt) was determined by immunoblotting. The
4T1MYBup variant was tested for migration (B) and invasion (C) activity using the xCELLigence RTCA as described in Figure 3. The panels
represent the average cell indexes at certain time points (6 h for migration and 12 h for invasion) from three (collagen I) and four (migration
and Matrigel invasion) independent measurements. Asterisks indicate significant (p < 0.05) differences in the migration (B) and Matrigel invasion
(C) of the myb-less vector-transfected cells and MYBup cells as determined by the t-test. Error bars indicate standard deviations.
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in liver and bones were similar in the control and
M Y B u pg r o u p sa sd e t e r m i n e db y histological examina-
tion (Figure 7B, D; Additional file 4). Taken together,
the results implicate that c-Myb participates in the
control of breast tumor growth and spontaneous
metastasis. Whereas c-Myb delays the outgrowth of
primary tumors and reduces their metastatic spread to
lungs, it does not affect the frequency or severity of
bone and liver metastases.
Figure 7 c-Myb delays mammary tumor growth and prevents the formation of pulmonary metastases.T h et u m o rg r o w t ha n d
spontaneous metastatic ability of the myb-less vector-transfected (control) 4T1 and 4T1M-M5 cell variant (MYBup) were determined following
orthotopic inoculation into the mammary fat pads of BALB/c mice. (A) Tumor growth was monitored twice a week by measuring the tumor
length (l) and width (w). Tumor volume was calculated using the equation l × w
2/2. The mice injected with the MYBup 4T1 variants (n = 9) and
control 4T1 cells (n = 9) were euthanized when the mean tumor diameter was approximately 1.2 cm. (B) Lungs were removed, rinsed in water,
and fixed in Bouin’s solution. Liver and bones were harvested and fixed in 10% buffered formalin. The number of lungs with surface metastases
was determined using dissecting microscopy, and metastases in liver and bones were determined by histological examination of H&E-stained
sections. Percentage of the mice with metastases (mts) developed in lung, liver and bones, respectively, is shown. (C) The surface metastatic
nodules per lungs (mts) exemplified under the graph were enumerated by examination using dissecting microscopy. Asterisks indicate
significant (p < 0.01) differences in the number of lung metastases in the mice injected with MYBup 4T1 variants and control 4T1 cells as
determined by the t-test. Error bars indicate standard deviations. Representative samples of Bouin’s solution-fixed tissues are shown. (D) Tissues
were processed for paraffin embedding, sectioned, and stained with H&E. Bones were decalcified overnight before embedding. The lung, liver,
and bone metastases were identified by light microscopy (arrows).
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In this report, we identified the regulation of MMP1/9
and cathepsin D by c-Myb as a novel mechanism of the
matrix-specific breast cancer cell invasion. c-Myb has
been recently identified as a regulator of tumor cell
motility and invasion, and the Slug transcription factor
was described as the mediator of the c-Myb-induced
mesenchymal-like phenotype in neuroblastoma, colon
carcinoma, and embryonic kidney cells [15]. The TGFb-
induced EMT and invasion of estrogen receptor-positive
breast cancer cells was also found to be dependent on
c-Myb expression [28]. In our study, we confirmed the
regulatory role of c-Myb in control of migration and
invasion of breast carcinoma cells as well. We also
observed upregulation of Slug in the MYBup variants of
MDA-MB-231 cells, but we did not detect any c-Myb-
dependent changes in expression of either epithelial or
mesenchymal cell markers, such as E-cadherin, N-cad-
herin, or vimentin (Additional file 5). This may presum-
ably result from the mesenchymal-like phenotype of the
parental MDA-MB-231 cells. We demonstrated that c-
Myb activates transcription of cathepsin D in a Slug-
independent manner (Additional file 6). This implies
that EMT is not an exclusive mode of c-Myb control
over cell migration/invasion. In hepatocellular tumor
cells, c-Myb stimulated migration/invasion via osteopon-
tin secretion [16]. Activation of the osteopontin promo-
ter by c-Myb was also reported in melanomas [29].
However, expression of the osteopontin gene was not
deregulated in the c-myb-overexpressing MDA-MB-231
cells (data not shown) implying that c-Myb uses another
mechanism to control migration/invasion of breast can-
cer cells.
There are two main types of ECM in vertebrates: BM
and the stromal/interstitial matrix. Components of the
BMs include collagen IV, laminin, perlecan, and nido-
gen. Stromal/interstitial matrices that form the majority
of the body connective tissues are composed primarily
of fibrillar collagen I. As both BM and stromal matrices
represent steric barriers to cell migration, matrix remo-
deling is a critical prerequisite for metastasis formation.
BM extract/Matrigel is frequently used to assess cell
invasive capacity in vitro. Matrigel invasion in vitro is
considered to simulate the penetration of BMs underly-
ing epithelial cells or blood vessels by tumor cells in
vivo. We documented that c-Myb induces the invasion
of MDA-MB-231 cells throughM a t r i g e l .C o n v e r s e l y ,
cancer cell invasion through stromal/interstitial matrices
composed primarily of fibrillar collagen I was found to
be critical for metastasis in several tumor types [22,23].
We found that c-Myb does not activate cell invasion
through the collagen I barrier. Modulation of cell inva-
sion by ECM components was described previously
[30-32]. Different invasion modes reflecting the specifi-
city of substrates may be attributed to the different
requirements on proteolytic systems [22,33]. Therefore,
we analyzed the expression of candidate proteases in c-
myb-overexpressing and control MDA-MB-231 cells and
confirmed the differential expression of MMP1, MMP9,
and cathepsin D. We confirmed the recent observation
by Bhattarai that the c-Myb upregulates MMP9 in
breast cancer cells [34]. Our demonstration that c-Myb
modulates MMP1 has not been described yet. While
cathepsin D and MMP9 were upregulated, the expres-
sion of MMP1 was considerably reduced in the MYBup
variants. c-Myb-induced Matrigel invasion is sensitive to
the broad spectrum MMP inhibitor GM6001 (Ilomastat;
Additional file 3). As MMP9 is the only MMP found to
be upregulated in MYBup cells and collagen IV, the
major component of the BM/Matrigel, is the main sub-
strate for MMP9, we hypothesize that apart from cathe-
psin D, the MMP9 is an effector of the c-Myb-induced
Matrigel invasion. MYBup cells exhibiting high MMP9
activity could transverse the Matrigel matrices more effi-
ciently than controls, even in the absence of MMP1.
MMP1 (interstitial collagenase) predominantly cleaves
collagen I; therefore, the lack of MMP1 in MDA-MB-
231MYBup cells might compromise their penetration
through the collagen I matrix. Cathepsin D might secure
partial invasion of these cells to collagen I substrates
[35], as shown by reduced collagen I penetration of
MDA-MB-231MYBup cells with silenced cathepsin D
expression (Figure 5).
We propose cathepsin D as a novel downstream med-
iator of the c-Myb migration/invasion-promoting func-
tion. Cathepsin D was suggested as one of the c-Myb-
target genes in MCF7 breast cancer cells previously [36].
Our results confirmed this observation in MDA-MB-231
cells. We identified multiple putative Myb-binding sites
in the human cathepsin D gene promoter using TESS
software (Additional file 7). There are conflicting results
regarding participation of the cathepsin D in the control
of breast cancer cell invasion and metastasis [37-44].
Johnson et al. observed that breast cancer cell invasion
did not reflect various release rates of cathepsin D from
different subclones of MCF7 cells [41]. Similarly,
Glondu et al. modulated cathepsin D expression using
antisense inhibition without any effect on invasiveness
of breast cancer cells in vitro [42]. In contrast, suppres-
sion of cathepsin D by antisense oligonucleotides and
shRNA in MCF7 and MDA-MB-231 cells, respectively,
associated with reduction of their invasion through
Matrigel was observed by others [43,44]. The effects of
siRNA-mediated silencing of cathepsin D in MDA-MB-
231MYBup cells described in our study provide further
support to the studies documenting the regulatory
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and invasiveness. Several hypotheses have been raised
concerning the mechanism how cathepsin D exerts its
effects in tumors. They include facilitated release of
growth factors, degradation of the extracellular matrix
to permit invasion of the tumor cells and proteolytic
activity-independent stimulation of the tumor cells via
protein-binding activity of cathepsin D. We observed
that unlike siRNA-mediated suppression of cathepsin D
expression, inhibition of its activity using pepstatin A
blocked neither migration nor invasion of MDA-MB-
231MYBup cells (data not shown). This implies that it is
the protein-binding activity of cathepsin D that may be
involved in stimulation of the tumor cells. Our results
correspond with studies documenting that catalytically
inactive mutants of cathepsin D stimulate cell invasion
[45,46]. Recently, the LRP1 cell surface receptor was
identified as a binding partner for pro-cathepsin D in
fibroblasts [47]. Breast cancer cells express LRP1 [48]
and the LRP-induced stimulation of cancer cell motility
and invasion was described elsewhere [49,50]. Therefore,
we can hypothesize that cathepsin D enhances migra-
tion/invasion of breast cancer cells via LRP1 signaling.
Despite the upregulation of MMP9 mRNA/protein
observed in the cells overexpressing c-myb, transient
transfection studies demonstrated no transactivation of
the reporter gene derived from the MMP9 promoter by
c-Myb. Similarly, c-Myb did not repress transcription
from the MMP1 promoter, although the level of MMP1
decreased in the MYBup cells. c-Myb was demonstrated
to act as a transcriptional transactivator/repressor
through specific binding to the promoter regions of tar-
get genes in numerous studies. However, there are also
reports demonstrating that c-Myb can affect gene
expression via indirect mechanisms [51,52]. We studied
the stability of the MMP9/1 transcripts using actinomy-
cin D and found that c-Myb does not affect the stability
of MMP9/1 mRNAs (data not shown). We hypothesize
that structural and functional differences between transi-
ently transfected plasmid DNA and genomic templates,
such as inefficient chromatinization, might explain why
c-Myb failed to transactivate/repress the MMP9/1 pro-
moters [53]. There are reports indicating that the Myb-
induced chromatin binding and remodeling are essential
for the transactivation of its target genes [54,55].
We demonstrated that murine c-Myb regulates migra-
tion/invasion of mouse 4T1 cells in vitro. 4T1 cells were
employed as orthotopic mammary tumor model because
they effectively metastasize and display metastatic char-
acteristics similar to those observed in cancer patients
[56]. Surprisingly, the c-myb-overexpressing 4T1 cells
injected into the mammary fat pads of BALB/c mice
exhibited delayed tumor growth and no formation of
spontaneous pulmonary metastases. Previous studies
d e s c r i b e dt h a tt h emyb genes can function either as
oncogenes or as tumor suppressors in different cellular
contexts [57] and there are conflicting results concern-
ing the c-myb function in breast cancer. Oncogenic role
of c-Myb was documented by c-myb knockdown in
estrogen receptor (ER)-positive breast cancer cell lines
resulting in block of estrogen-dependent proliferation
[58] and TGFb-induced invasiveness in vitro [28]. Miao
et al. have recently published data documenting that
established human breast cancer xenografts do not
advance when c-Myb is knocked down using shRNA
[59]. The tissue-specific deletion of c-myb also interferes
with mammary tumorigenesis in mouse mammary
tumor virus (MMTV)-NEU and MMTV-PyMT mice
[59]. On the other hand, there is also report that c-myb
depletion increases the cell growth and tumorigenesis of
MCF7 breast cancer cells both in vitro and in vivo [17]
documenting that c-Myb can also act as tumor suppres-
sor. The data based on human breast cancer microarray
expression analysis in vivo showed that high c-Myb
expression is associated with a good outcome and high
differentiation status of the tumors [17]. Similarly, a
unique subgroup of estrogen receptor-positive human
breast cancers with 100% overall survival, no metastatic
potential, and high c-myb expression has been described
recently [60]. Our study of ectopic c-myb overexpression
in a mouse orthotopic tumor model supports the view
of c-Myb as tumor-suppressor in breast cancer. The c-
Myb-controlled expression of Hep27 gene was suggested
as a mechanism how c-Myb exerts its tumor-suppres-
sing function in ER-positive breast cancer [17,60].
Hep27 inhibits Mdm2 thereby stabilizes p53 [61].
Therefore, the c-Myb-Hep27-Mdm2-p53 signaling path-
way may have functional significance for ER- and
p53wt-positive breast cancers cells [61]. Interestingly,
good prognosis of patients with ER-negative basal-like
subtype of breast tumors with frequently mutated p53
was also associated with high c-myb expression [17]. To
date, the function of c-Myb in metastasis formation in
mouse models has not been clarified. It was demon-
strated, however, that c-Myb promotes the bone marrow
homing of leukemic cells [15]. Our study showed that
overexpressed c-Myb can suppress the formation of pul-
monary metastases in a mouse model of mammary car-
cinoma. We propose that interstitial collagenase may be
one of the mediators of the tumor- and metastasis-sup-
pressing function of c-Myb in ER-negative breast cancer
cells because interstitial collagenase was clearly downre-
gulated in MDA-MB-231MYBup cells (Figure 4),
4T1MYBup cells (Additional file 8) and in the c-myb-
overexpressing tumors (Additional file 8). A number of
observations support this hypothesis. Upregulation of
MMP1 was previously associated with advanced stages
of breast cancer, and it was thus suggested as a
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ease [62]. The shRNA-mediated silencing of MMP1
inhibited growth of MDA-MB-231 cells orthotopically
implanted into the mammary fat pads of nude mice
[63]. The requirement for MMP1 for breast tumor
growth was partly attributed to breakdown of the
fibrous stroma within the mammary fat pad and partly
to the liberation of growth factors present in ECM [63].
In addition, the MMP1/protease-activated receptor 1
signaling axis promoting mammary tumor growth and
metastasis was identified [64-66]. In addition, Gupta et
al. reported that MMP1 silencing in combination with
epiregulin (EREG), cyclooxygenase 2 (COX2),o rMMP2
delayed tumor progression [67]. Interestingly, MMP1,
EREG,a n dCOX2 are parts of the clinically validated
lung metastasis signature [68]. This signature comprises
genes marking and mediating breast cancer metastasis
to the lungs. MMP1 belongs to the family of genes with
dual functions conferring both breast tumorigenicity
and lung metastagenicity [68,69].
Moreover, MMP1 has been implicated in pulmonary
extravasation [67,70]. The barriers to metastasis are dis-
tinct in different organs [71,72]. The lung vascular
endothelial junctions act as barriers limiting cell passage.
In contrast, the bone marrow and liver vasculature con-
sists of capillary vascular channels possessing a discon-
tinuous endothelium [71,73]. Therefore, lung metastases
may require robust extravasation such as those provided
by MMP1, EREG, COX2,a n dMMP2 [67,71]. In con-
trast, the requirement for effective extravasation is not
principal for bone and liver metastasis [71,73,74]. These
findings correspond with our results revealing organ-
specific differences in the metastatic ability of c-myb-
overexpressing cells. The deficit of MMP1 function in
the c-myb-overexpressing cells may contribute to the
selective disadvantage of these cells in lung colonization.
However, they can still initiate metastasis in bone and
liver.
We demonstrated that enhanced migration and inva-
sion of c-myb-overexpressing breast cancer cells through
Matrigel in vitro does not imply increased metastatic
capacity. Inconsistency in proinvasive behavior of tumor
cells in vitro and metastatic potential in mouse xeno-
graft models in vivo was also described previously
[75,76]. It was postulated that the capacity of tumor
cells to metastasize is determined not only by the inher-
ent characteristics of the cancer cells, such as motility
and in vitro invasiveness, but it is also modulated by the
cancer cell microenvironment, such as ECM deposition,
the presence of other proteases, cytokines, growth fac-
tors and adaptor proteins [75-77]. Apparently, there are
tissue-specific factors in the host that participate in the
control of cancer cell invasiveness [78].
Conclusions
In this report, we identified the regulation of MMP1/9
and cathepsin D by c-Myb as a novel mechanism of
breast cancer cell invasion that is dependent on extra-
cellular matrix composition. We documented that c-
Myb regulates breast cancer metastases in an organ-spe-
cific manner. These findings provide new clues for
understanding of the oncogenic/tumor-suppressing
functions of c-myb and for future clinical applications.
Methods
Plasmids
Constructs encoding human (pcDNA3-hcMYB) and
mouse c-Myb proteins (pcDNA3-mcMYB) were kindly
provided by J. Bies [79]. The reporter construct p6MBSluc
containing six Myb-binding sites upstream of luciferase
cDNA was kindly provided by T. Nakano [80]. CMV-bgal
was described elsewhere [81]. Reporter constructs with
cathepsin D promoter sequences (2.85 and 0.82 kb) in
pGL3 were kindly provided by J. Chirgwin [82]. Reporter
constructs containing the MMP1 promoter sequences
(4.3-1 G, 1.606, and 0.624 kb) in pGL3 were kindly pro-
vided by C. E. Brinckerhoff [83] and A. Galloway [84]. The
MMP9 promoter sequence (-1362/+19) was obtained
from the genomic DNA of human blood cells by PCR
using the forward primer 5’-GCGCGCAGATCTTATA-
GACCCTGCCCGATGCCGG-3’ and the reverse primer
5’-GCGCGCAAGCTTTGGTGAGGGCAGAGGTGTCT-
GAC-3’. The PCR product was cut with BglII/HindIII and
ligated into pGL2-basic (Promega, Madison, WI).
Cells and transfection
Human MDA-MB-231 and mouse mammary carcinoma
4T1 cells obtained from American Type Culture Collec-
tion were cultured in RPMI 1640 (Sigma, St. Louis,
MO) supplemented with 10% FCS, 2 mM L-glutamine
100 U/ml penicillin and 100 μg/ml streptomycin. Med-
ium for 4T1 cells was supplemented with 4500 mg/l
glucose and 1 mM sodium pyruvate. MDA-MB-231
cells were transfected with the pcDNA3-hcMYB plasmid
and the myb-less control plasmid. 4T1 cells were trans-
fected with the pcDNA3mcMYB plasmid and the myb-
less control plasmid. Transfections were performed
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. Transfec-
tants were selected with 800 μg/ml G418 (MDA-MB-
231 cells) and 300 μg/ml G418 (4T1 cells) and cloned
by limiting dilution.
Transmigration/invasion assay
Cell migration and invasion were analyzed using Cultrex
cell invasion assay (Trevigen, Gaithersberg, MD) accord-
ing to the manufacturer’s instructions. Briefly, for the
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96-well plate was coated with 0.5 × basement membrane
matrix/Matrigel. For the transmigration assay, the mem-
brane was left uncoated. MDA-MB-231 cells were
starved in the serum-free medium for 8 hours prior
assay, then seeded at a density 5 × 10
4/well. After 16 h,
the cells on the lower surface were dissociated and
stained with the Calcein-AM. The amount of emitted
fluorescence was determined by Synergy HT microplate
reader (Bio-tek, Winooski, VT) to quantify the relative
cell migration/invasion.
Kinetics of cell migration/invasion
To monitor cell migration/invasion in real time, we
used the xCELLigence Real-Time Cell Analyzer (RTCA)
DP Instrument equipped with a CIM-plate 16 (Roche,
Indianapolis, IN). The CIM-plate 16 is a 16-well system
in which each well is composed of upper and lower
chambers separated by an 8-μm microporous mem-
brane. Migration/invasion was measured as the relative
impedance change (cell index) across microelectronic
sensors integrated into the bottom side of the mem-
brane. For the cell invasion experiments, the membrane
was coated with either Matrigel (BD Biosciences, San
José, CA) or collagen I (Sigma, St. Louis, MO). Matrigel
was diluted 1:40 in serum-free medium and allowed to
polymerize at 37°C for 4 h. The collagen solution was
neutralized with NaOH and allowed to form a 3D gel at
37°C for 1 h. For the cell migration experiments, the
membrane was left uncoated. FCS (10%) was used as a
chemoattractant. Cells were starved in a serum-free
media for 8 h. Cells (7.5 × 10
4) were added in dupli-
cates to the upper chambers. Migration/invasion was
monitored every 10 or 15 min for several hours. For
quantification, the cell index at indicated time points
w a sa v e r a g e df r o ma tl e a s tt h r e ei n d e p e n d e n t
measurements.
RNA isolation and quantitative RT-PCR
Total RNA was isolated from MDA-MB-231 cells using
an RNeasy mini kit (Qiagen, Valencia, CA) according to
the manufacturer’si n s t r u c t i o n s .R N A( 0 . 5μg) was used
for first-strand cDNA synthesis with the QuantiTect
Reverse Transcription kit (Qiagen, Valencia, CA).
Human MMP2, 3, 7, 10, 11, 13 mRNA were quantified
by qRT-PCR with specific primers and RT
2 SYBR
Green/ROX PCR Master Mix (SABiosciences, Frederick,
MD). Human c-myb, cathepsin D, MMP9,a n dMMP1
mRNAs were quantified by qRT-PCR using specific
TaqMan probes (Applied Biosystems, Foster City, CA).
GAPDH was used as an internal control. All PCR reac-
tions were performed in triplicate for each sample and
were repeated at least three times. The qRT-PCR data
were analyzed by the ΔΔCt method.
Immunoblotting
Cell lysates were subjected to SDS-PAGE and immu-
noblotted as previously described [85]. The condi-
tioned media were concentrated using Amicon Ultra
Centrifugal Filters with the Ultracel-10 membrane
(Millipore, Billerica, MA). Protein concentrations were
determined using the DC protein assay (Bio-Rad, Her-
cules, CA). Equal amounts of total protein (30 μg)
were loaded. Blots were probed with anti-Myb (05-175,
Millipore, Billerica, MA), anti-cathepsin D (610801, BD
Biosciences, San José, CA), anti-MMP1 (1976-S, EpiSe-
lect MMP sampler kit, Epitomics, Burlingame, CA),
and anti-MMP9 (G657, Cell Signaling Technology,
Beverly, MA) antibodies. To control for sample load-
ing, the blots were probed with a b-actin-specific anti-
body (A5060, Sigma, St. Louis, MO). Blots were
developed by standard ECL procedure using Immobi-
lon Western Chemiluminiscent HRP Substrate (Milli-
pore, Billerica, MA).
Cathepsin D assay
The cells (9 × 10
5) were collected in 80 μl of sterile-fil-
tered water and subjected to three freeze-thaw cycles.
After centrifugation at 25 000 × g for 5 min, 20 μgo f
cell extracts were subjectedt ot h eC a t h e p s i nDA s s a y
(Sigma, St. Louis, MO) according to the manufacturer’s
instructions. Pepstatin A was added to determine the
cathepsin D-specific fluorescence signals. The plates
were incubated at 37°C for 30 min, and readings were
performed in 2-min intervals using a Synergy HT micro-
plate reader (Bio-tek, Winooski, VT).
Transactivation assay
To determine transactivation by c-Myb, MDA-MB-231
wt, vector, and MYBup cells were transiently cotrans-
fected with p6MBSluc/pGL3-CD/pGL2-MMP9/pGL3-
MMP1 and CMV-bgal plasmids using Lipofectamine
2000 (Invitrogen, Carlsbad, CA) according to the manu-
facturer’s instructions. Cells were cultured for 24 h and
processed for luciferase and b-galactosidase assays as
described elsewhere [86]. The luciferase activity of each
sample was expressed in relative light units and normal-
ized for transfection efficiency according to the b-galac-
tosidase activity.
Cathepsin D/c-myb knockdown using siRNA
The cathepsin D siRNA oligos (5’-GGAUCCCGCUGCA-
CAAGUUTT-3’) were purchased from Ambion (Austin,
TX). The c-myb siRNA oligos (5’-UAUAGUGUCUCU-
GAAUGGCUGCGGC-3’) were purchased from Invitrogen.
ON-TARGETplus nontargeting pool siRNA (Dharmacon,
Lafayette, CO) was used as a negative control. Transfection
with siRNA was performed using xtremeGENE siRNA
transfection reagent according to the manufacturer’s
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nM, final concentration) was added to the plates for 3 h.
After 72 h, the cells were processed for a cell migration
assay as described above. At the same time, the cells were
harvested, and cathepsin D/c-Myb expression was deter-
mined by immunoblotting.
Metastasis assay
To evaluate the formation of spontaneous metastases,
c-myb-overexpressing and control 4T1 tumor cells
(1 × 10
5 in a 20-μl Matrigel:PBS solution, 1:1) were
injected into the fourth mammary fat pad of female
BALB/c mice aged 6-8 weeks. The use of these animals
followed the European Community Guidelines as
accepted principles for the use of experimental ani-
mals. The experiments were performed with the
approval of the Institutional Ethical Committee.
Tumor growth was monitored at least twice a week by
measuring the tumor length (l) and width (w) with
caliper, and tumor volume was calculated using the
equation l × w
2/2. The mice were euthanized when the
mean tumor diameter was approximately 1.2 cm [87].
Tumors were excised and weighed. Lungs were fixed in
Bouin’s solution, and liver and bones were fixed in
10% buffered formalin. Surface metastatic nodules in
lungs were determined by dissecting microscopy.
Lungs, liver and bone tissues were processed for paraf-
fin embedding, sectioned, and stained with hematoxy-
lin and eosin (H&E). Bones were decalcified overnight
before embedding. The number of pulmonary meta-
static lesions was determined by histological examina-
tion. Every 10th consecutive section was examined for
the presence of metastases. The extent of liver and
bone metastases was evaluated semi-quantitatively by
light microscopy.
Statistics
Values were expressed as means ± standard deviations.
To determine statistical significance, the values were
compared by unpaired two-tailed t-test. Differences
were considered to be significant at p < 0.05.
Additional material
Additional file 1: Figure S1 Kinetics of c-Myb-induced migration and
Matrigel invasion of MDA-MB-231MYBup cells. Cell migration/
invasion was analyzed in real time by the xCELLigence RTCA as
described in Figure 3. The panels show the average cell indexes at
indicated time points from seven (migration) and five (invasion)
independent experiments. Error bars indicate standard deviations.
Asterisks indicate significant (p < 0.05) differences in the migration/
Matrigel invasion of the myb-less vector-transfected cells and MYBup
cells (M2, M5) as determined by the t-test.
Additional file 2: Figure S2 siRNA-mediated c-myb silencing reduces
migration and Matrigel invasion activities of MDA-MB-231MYBup
cells. MDA-MB-231MYBup cells were transfected with c-myb (MYB) or
control (ctrl) siRNAs as described in the Material and Methods. The level
of c-Myb protein in these cells was determined by immunoblotting. A
representative western blot is presented (A). Migration and invasion
activities of the same cells were determined by the xCELLigence RTCA.
The chart shows the representative outcomes of the kinetics analysis of
cell migration (B). The average cell indexes at the 6-h (migration, left)
and 12-h (invasion, right) time points, respectively, from four
independent measurements are shown (C). Error bars indicate standard
deviations. Asterisks indicate significant (p < 0.05) differences in the
migration/invasion rates of the cells transfected with c-myb siRNA and
control siRNA as determined by the t-test.
Additional file 3: Figure S3 c-Myb-induced Matrigel invasion is
sensitive to the MMP inhibitor GM6001. MDA-MB-231MYBup cells (M2,
M5) were starved in the serum-free medium for 8 h and processed for
cell invasion assay as described in the Material and Methods. The
membranes were coated with the diluted Matrigel. The broad-spectrum
MMP inhibitor GM6001 (Sigma) at final concentration of 20 μM or DMSO
were added to the bottom and upper chambers of indicated wells of
CIM-plate 16. The bottom chambers were filled with complete medium
containing 10% FCS as a chemoattractant. (A) The chart shows the
representative outcomes of kinetics analysis of Matrigel invasion. (B) The
columns show the average cell indexes in 12 h time point from three
independent measurements. Error bars indicate standard deviations.
Asterisks indicate significant (p < 0.05) differences in Matrigel invasion of
the GM6001-treated MDA-MB-231MYBup cells and DMSO-treated MDA-
MB-231MYBup controls as determined by the t-test.
Additional file 4: Figure S4 Histological examination of lungs, liver
and bones of BALB/c mice orthotopically injected with c-myb
overexpressing (MYBup) and control 4T1 cells. Lungs were fixed in
Bouin’s solution. Liver and bones were harvested and fixed in 10%
buffered formalin. Tissues were processed for paraffin embedding,
sectioned, and stained with hematoxylin and eosin. Bones were
decalcified overnight before embedding. (A) The mean number of
pulmonary metastatic lesions as determined by histological examination.
Every 10th consecutive section was examined for the presence of
metastases (mts). (B) Semi-quantitative evaluation of liver metastasis: +
rare microscopic neoplastic lesions, ++ numerous microscopic lesion, ++
+ numerous extensive neoplastic lesions. (C) Semi-quantitative evaluation
of skeletal metastasis: + epithelial tumor cell infiltration and bone
destruction, ++ tumor cell infiltration and bone destruction with the
invasion of soft tissues.
Additional file 5: Figure S5 c-Myb upregulates Slug in MDA-MB-
231MYBup cells. The nontransfected (wt), the myb-less vector-
transfected (vector) and MYBup (M2, M5) cells were harvested. Protein
extracts were resolved by SDS-PAGE and analyzed by immunoblotting
with anti-Slug (9585, Cell Signaling), anti-vimentin (13.2, Sigma) and anti-
N-cadherin (610920, BD Biosciences) antibodies. To control for sample
loading, the blots were probed with the b-actin-specific antibody.
Additional file 6: Figure S6 c-Myb induces the cathepsin D
transcription independently on Slug. MDA-MB-231 cells were
transiently cotransfected with either c-myb (MYBup), Slug cDNA (SLUGup)
or the empty vector (vector) and the reporter plasmids (the 2.85 kb- or
0.82 kb pGL3-CD containing segments of cathepsin D promoter of
indicated lengths upstream of the luciferase gene, and CMV-bgal) and
harvested 48 h later. (A) The amounts of c-Myb and Slug proteins were
determined by immunoblotting. (B) The luciferase activity of each
sample was expressed in relative light units and normalized for
transfection efficiency according to the b-galactosidase activity. The
columns show the average relative luciferase activity from three
independent measurements. Error bars indicate the standard deviations.
Asterisks indicate significant (p < 0.05) differences in the luciferase
activity in the empty vector-transfected cells and cells transfected with c-
myb cDNA as determined by the t-test.
Additional file 7: Figure S7 TESS analysis of 2.5 kb promoter region
of human cathepsin D gene. Lines indicate putative Myb-binding sites
identified with the Transcription Element Search Software (TESS; http://
www.cbil.upenn.edu/cgi-bin/tess/).
Additional file 8: Figure S8a c-Myb down-regulates interstitial
collagenase Mmp1a in 4T1 cells. The control (wt, vector) and the
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immunoblotting. To control for sample loading, the blots were probed
with a b-actin-specific antibody. The secretion of Mmp1a was
determined in the cell-conditioned medium. The cells were cultured in a
serum-free medium for 8 h, and the medium was harvested and
concentrated using the Amicon Ultra centrifugal filter units. Equal
amounts of total proteins were loaded. Figure S8b Expression of c-myb
and mmp1a mRNAs in 4T1 MYBup and control tumors. Total RNA was
isolated from mouse mammary tumors. The relative amounts of c-myb
and mmp1a mRNAs in the MYBup and control tumors were determined
by qRT-PCR. GAPDH was used as an internal control. Asterisks indicate
significant (p < 0.05) differences in the relative amounts of c-myb and
mmp1a mRNAs in the control and MYBup tumors as determined by the
t-test.
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